122 related articles for article (PubMed ID: 31938149)
21. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
[TBL] [Abstract][Full Text] [Related]
23. Sox2 inhibits Wnt-β-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells.
He J; Shi J; Zhang K; Xue J; Li J; Yang J; Chen J; Wei J; Ren H; Liu X
Mol Med Rep; 2017 Apr; 15(4):1693-1701. PubMed ID: 28259951
[TBL] [Abstract][Full Text] [Related]
24. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt.
Xu Z; Mei J; Tan Y
Int J Oncol; 2017 Jan; 50(1):93-100. PubMed ID: 27878245
[TBL] [Abstract][Full Text] [Related]
25. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
26. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
27. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
[TBL] [Abstract][Full Text] [Related]
28. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
29. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
30. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway.
Liu Y; Chen X; Gu Y; Zhu L; Qian Y; Pei D; Zhang W; Shu Y
Neoplasma; 2015; 62(1):61-71. PubMed ID: 25563368
[TBL] [Abstract][Full Text] [Related]
32. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
33. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.
Hu W; Jin P; Liu W
Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
35. Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway.
Qi K; Li Y; Li X; Lei X; Wang B; Zhang L; Chu X
Anticancer Drugs; 2016 Nov; 27(10):970-8. PubMed ID: 27537399
[TBL] [Abstract][Full Text] [Related]
36. GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells.
Zhang N; Yang GQ; Shao XM; Wei L
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2271-7. PubMed ID: 27338051
[TBL] [Abstract][Full Text] [Related]
37. Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells.
Zhang Q; Zhu H; Xu X; Li L; Tan H; Cai X
Biochem Biophys Res Commun; 2015 Sep; 465(1):64-70. PubMed ID: 26235873
[TBL] [Abstract][Full Text] [Related]
38. Significance of SALL4 as a drug‑resistant factor in lung cancer.
Yanagihara N; Kobayashi D; Kuribayashi K; Tanaka M; Hasegawa T; Watanabe N
Int J Oncol; 2015 Apr; 46(4):1527-34. PubMed ID: 25646965
[TBL] [Abstract][Full Text] [Related]
39. Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway.
Yang J; Zhang K; Wu J; Shi J; Xue J; Li J; Chen J; Zhu Y; Wei J; He J; Liu X
Stem Cells Int; 2016; 2016():1690896. PubMed ID: 27895670
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of miR-141 reverses cisplatin resistance in non-small cell lung cancer cells via upregulation of programmed cell death protein 4.
Fu WF; Chen WB; Dai L; Yang GP; Jiang ZY; Pan L; Zhao J; Chen G
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2565-72. PubMed ID: 27383306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
